Phase 1 9 trials
Phase 1
NCT07581704 Jun 2026 → Jun 2029 expected plasma cell myeloma Christopher Strouse
Recruiting
No outcome recorded
Phase 1
NCT07032714 Dec 2025 → Jul 2027 expected refractory plasma cell neoplasm Massachusetts General Hospital
Recruiting
No outcome recorded
Phase 1
NCT07093554 Dec 2025 → Jul 2027 expected plasma cell myeloma Medical College of Wisconsin
Recruiting
No outcome recorded
Phase 1
NCT06348108 Jul 2025 → Jul 2027 expected plasma cell myeloma Alfred Chung, MD
Recruiting
No outcome recorded
Phase 1
NCT05338775 May 2022 → May 2025 overdue refractory plasma cell neoplasm Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 1
NCT05050097 Sep 2021 → Mar 2025 overdue plasma cell myeloma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 1
NCT04773522 May 2021 → Oct 2022 plasma cell myeloma Janssen Pharmaceutical K.K.
Completed
No outcome recorded
Phase 1
NCT04108195 Feb 2020 → Apr 2027 expected plasma cell myeloma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 1
NCT03399799 Dec 2017 → Jul 2022 overdue hematopoietic and lymphoid cell neoplasm Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 1/2 2 trials
Phase 1/2
NCT06572605 Aug 2025 → Jan 2030 expected extramedullary plasmacytoma , plasma cell myeloma City of Hope Medical Center
Recruiting
No outcome recorded
Phase 1/2
NCT04586426 Dec 2020 → Mar 2025 overdue plasma cell myeloma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 2 16 trials
Phase 2
NCT07029776 Jul 2026 → Apr 2030 expected plasma cell myeloma University of Arkansas
Not yet recruiting
No outcome recorded
Phase 2
NCT07107529 Dec 2025 → Apr 2029 expected plasma cell myeloma European Myeloma Network B.V.
Recruiting
No outcome recorded
Phase 2
NCT06827860 Nov 2025 → Jan 2027 expected plasma cell myeloma Larysa Sanchez
Recruiting
No outcome recorded
Phase 2
NCT06993675 Aug 2025 → Aug 2029 expected plasma cell myeloma Noffar Bar
Recruiting
No outcome recorded
Phase 2
NCT06461988 Jun 2025 → Dec 2027 expected disease related to hematopoietic stem cell transplant , plasma cell myeloma Stanford University
Recruiting
No outcome recorded
Phase 2
NCT06550895 Sep 2024 → Aug 2027 expected plasma cell myeloma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 2
NCT06500884 Aug 2024 → May 2030 expected plasma cell myeloma Janssen Research & Development, LLC
Recruiting
No outcome recorded
Phase 2
NCT06577025 Aug 2024 → Sep 2030 expected plasma cell myeloma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 2
NCT06353022 Jun 2024 → Apr 2028 expected plasma cell myeloma Nantes University Hospital
Active not recruiting
No outcome recorded
Phase 2
NCT06505369 Jun 2024 → Nov 2026 expected plasma cell myeloma North Estonia Medical Centre
Recruiting
No outcome recorded
Phase 2
NCT06100237 Dec 2023 → Dec 2028 expected plasma cell myeloma Carl Ola Landgren, MD, PhD
Recruiting
No outcome recorded
Phase 2
NCT05972135 Oct 2023 → Aug 2027 expected plasma cell myeloma SCRI Development Innovations, LLC
Recruiting
No outcome recorded
Phase 2
NCT06066346 Sep 2023 → Oct 2027 expected plasma cell myeloma Memorial Sloan Kettering Cancer Center
Recruiting
No outcome recorded
Phase 2
NCT05849610 Sep 2023 → Mar 2026 overdue —
PETHEMA Foundation
Active not recruiting
No outcome recorded
Phase 2
NCT05695508 Dec 2022 → Sep 2028 expected plasma cell myeloma University of Heidelberg Medical Center
Recruiting
No outcome recorded
Phase 2
NCT04634552 Feb 2021 → Jun 2027 expected hematopoietic and lymphoid cell neoplasm Janssen Research & Development, LLC
Recruiting
No outcome recorded
Show 6 more trials Phase 3 5 trials
Phase 3
NCT07649525 Jul 2026 → Jun 2033 expected plasma cell leukemia , plasma cell myeloma University of Leeds
Recruiting
No outcome recorded
Phase 3
NCT06208150 Jan 2024 → Apr 2026 overdue plasma cell myeloma Janssen Research & Development, LLC
Recruiting
No outcome recorded
Phase 3
NCT05552222 Oct 2022 → Apr 2031 expected plasma cell myeloma Janssen Research & Development, LLC
Recruiting
No outcome recorded
Phase 3
NCT05461209 Oct → Nov 2022 refractory plasma cell neoplasm Janssen Research & Development, LLC
Withdrawn
No outcome recorded
Phase 3
NCT05455320 Oct 2022 → Jul 2027 expected plasma cell myeloma Janssen Research & Development, LLC
Active not recruiting
No outcome recorded
Phase 4 1 trial
Phase 4
NCT07474961 Mar 2027 → Dec 2036 expected Waldenstrom macroglobulinemia , plasma cell myeloma Anne Louise Tølbøll Sørensen
Not yet recruiting
No outcome recorded
Phase not applicable 1 trial
— NCT07499323 Mar 2026 → Mar 2027 expected generalized myasthenia gravis First Affiliated Hospital of Chongqing Medical University
Not yet recruiting
No outcome recorded
Phase not stated 2 trials
— NCT05757973 — refractory plasma cell neoplasm Janssen Research & Development, LLC
Approved for marketing
No outcome recorded
— NCT05503550 — refractory plasma cell neoplasm Janssen Research & Development, LLC
No longer available
No outcome recorded